61 completed. 61 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 61 | Completed 61 |
Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder. Pyridostigmine oral tablet, Placebo - Underactive Bladder, TURP(transurethral Resection of Prostate) | Phase 4 | Completed | Menoufia University | 66 | 2024-04-01 | 2025-03-26 |
| Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients With Prostate Volumes ≤ 40 ml: A Prospective Comparative Study Tamsulosin 0.4 mg, Tadalafil 5mg, Tamsulosin and Tadalafil - BPH With Other Lower Urinary Tract Symptoms | Phase 4 | Completed | Fayoum University Hospital | 95 | 2023-04-20 | 2025-02-05 |
| The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH Silodosin, Tamsolusin - BPH (Benign Prostatic Hyperplasia) | Phase 4 | Completed | Shanghai Huilun Pharmaceutical Co., Ltd. | 110 | 2022-07-18 | 2025-08-21 |
| Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain Self-Administered Nitrous Oxide, Oxygen - Prostate Disease, Malignancy | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 143 | 2021-12-12 | 2024-01-30 |
| Deprescribing Tamsulosin in Older Men Tamsulosin, Placebo - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Completed | University of California, San Francisco | 31 | 2021-09-18 | 2025-08-22 |
| Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP) Tranexamic acid - Kidney Calculi, Urologic Diseases | Phase 4 | Completed | Northwestern University | 110 | 2021-09-17 | 2026-10-15 |
| Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome 1% Atropine drops, Epinephrine - Intraoperative Floppy Iris Syndrome, Cataract | Phase 4 | Completed | University Hospital Olomouc | 164 | 2020-07-01 | 2024-02-20 |
| Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Silodosin, Tamsulosin - Benign Prostatic Hyperplasia | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 141 | 2017-08-31 | 2019-09-27 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Mirabegron, Placebo, Tamsulosin Hydrochloride - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Completed | Astellas Pharma Global Development, Inc. | 715 | 2016-06-13 | 2024-11-12 |
| Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool - Prostatic Hyperplasia | Phase 4 | Completed | GlaxoSmithKline | 1679 | 2016-05-12 | 2021-01-05 |
| A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) Mirabegron, Placebo, Tamsulosin - Overactive Bladder | Phase 4 | Completed | Astellas Pharma Inc | 568 | 2016-01-25 | 2024-11-12 |
| Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms Tadalafil, Placebo - Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Completed | University of Florence | 86 | 2015-12-01 | 2021-04-28 |
| The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Alfuzosin Hydrochloride 10 MG, Tamsulosin Hydrochloride 0.4 MG - Benign Prostatic Hyperplasia, Pupil Anomaly | Phase 4 | Completed | Kocatepe University | 63 | 2015-10-29 | 2017-05-09 |
| Benign Prostatic Hyperplasia and Ischemic Heart DIsease Tamsulosin Oral Capsule, TURP - Ischaemic Heart Disease (IHD), Benign Prostatic Hyperplasia (BPH) | Phase 4 | Completed | I.M. Sechenov First Moscow State Medical University | 83 | 2015-09-01 | 2019-02-27 |
| A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). Tadalafil, Placebo, Alpha1 Blocker - Benign Prostatic Hyperplasia | Phase 4 | Completed | Eli Lilly and Company | 171 | 2015-04-01 | 2017-07-02 |
| A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy ciprofloxacin, ciprofloxacin and gentamycine, culture based chemoprophylaxis - Benign Prostate Hyperplasia | Phase 4 | Completed | Mansoura University | 510 | 2015-04-01 | 2017-04-04 |
| GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Greenlight laser PVP, Bipolar TUVP - Benign Prostatic Hyperplasia | Phase 4 | Completed | Mansoura University | 120 | 2014-09-01 | 2019-06-12 |
| PERmixon® in LUTS Evaluation Study (PERLES) Permixon® 160 mg, Tamsulosine LP, Placebo matching Permixon® 160 mg - Benign Prostatic Hyperplasia (BPH) | Phase 4 | Completed | Pierre Fabre Medicament | 833 | 2014-04-01 | 2016-09-02 |
| Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Silodosin, Laboratory tests, 3-days voiding diary - Nocturia, Benign Prostatic Hyperplasia | Phase 4 | Completed | JW Pharmaceutical | 135 | 2014-01-02 | 2017-03-10 |
| Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Ertapenem - Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 20 | 2013-12-01 | 2025-09-08 |
Showing 20 of 61. Sign in to see all of them.
Lower Urinary Tract Symptoms (14) · Urinary Bladder, Overactive (6) · Hypogonadism (2) · Nocturia (2) · Prostatic Neoplasms (2) · Anxiety Disorders (1) · Cataract (1) · Choroid Diseases (1) · Coronary Artery Disease (1) · Ejaculatory Dysfunction (1) · Erectile Dysfunction (1) · Hyperplasia (1) · Kidney Calculi (1) · Kidney Diseases (1)
Genital Diseases (61) · Genital Diseases, Male (61) · Male Urogenital Diseases (61) · Urogenital Diseases (61) · Prostatic Diseases (60) · Pathological Conditions, Signs and Symptoms (25) · Signs and Symptoms (23) · Urological Manifestations (21) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Urologic Diseases (8) · Lower Urinary Tract Symptoms (7) · Urinary Bladder Diseases (7) · Endocrine System Diseases (2) · Eye Diseases (2)
Tamsulosin (16) · Dutasteride (7) · alfuzosin (7) · silodosin (6) · Tadalafil (4) · Solifenacin Succinate (3) · mirabegron (2) · saw palmetto extract (2) · 5-alpha Reductase Inhibitors (1) · Adrenergic alpha-1 Receptor Antagonists (1) · Atracurium (1) · Ciprofloxacin (1) · Clinical Laboratory Techniques (1) · Combined Modality Therapy (1) · Doxazosin (1)
GlaxoSmithKline (5) · Astellas Pharma Inc (4) · Boehringer Ingelheim (4) · Samsung Medical Center (4) · Sanofi (4) · JW Pharmaceutical (3) · Mansoura University (2) · Pierre Fabre Medicament (2) · Siami, Paul F., M.D. (2) · University of Florence (2) · American Medical Systems (1) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Korea, Inc. (1) · Astellas Pharma Taiwan, Inc. (1)
United States (11) · South Korea (10) · Italy (8) · France (7) · Spain (6) · Egypt (5) · Germany (5) · Netherlands (4) · Canada (3) · Czechia (3) · Japan (3) · Taiwan (3) · Greece (2) · Hungary (2) · United Kingdom (2)
Kyu-Sung Lee, Ph.D (4) · Ahmed M Elshal, MD (2) · Paul F Siami, MD (2) · Albert Dahan, MD {hD (1) · Alexis Te, MD (1) · Alvin M Matsumoto, MD (1) · Andrey Z Vinarov, PhD (1) · Benedict Blayney, MD (1) · Benjmain N Breyer, MD, MAS (1) · Christopher R Chapple, MD (1) · Claus G Roehrborn, MD (1)
PMID 16465187, PMID 19394149, PMID 19732305, PMID 21251673, PMID 21575967, PMID 21738005, PMID 22010203, PMID 23452344, PMID 25261801, PMID 25613154, PMID 26544316, PMID 27324263, PMID 29044968, PMID 29394114, PMID 31148056, PMID 31961963, PMID 32558340, PMID 33245533, PMID 36222618, PMID 37160401, PMID 40977319, PMID 42406401
2014 (1), 2015 (1), K12DK111028 (1)